Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

Egetis Therapeutics

5.90 SEK

-0.84 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.84 %
+28.54 %
+10.49 %
+10.49 %
+5.73 %
+46.04 %
-25.60 %
+5.59 %
-57.36 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.5B SEK
Turnover
1.7M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29.4
2026

Interim report Q1'26

6.5
2026

General meeting '26

21.8
2026

Interim report Q2'26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release3/27/2026, 3:42 PM

Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency

Egetis Therapeutics
Regulatory press release3/24/2026, 2:05 PM

Egetis Therapeutics’ Annual Report 2025 published

Egetis Therapeutics
Regulatory press release3/12/2026, 11:02 AM

NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/9/2026, 6:00 AM

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Egetis Therapeutics
Press release3/5/2026, 9:56 AM

Redeye: Egetis Therapeutics (Q4 review): US approval on the horizon

Egetis Therapeutics
Press release3/2/2026, 4:10 PM

Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q4'25
Webcast2/26/2026, 9:00 AM

Egetis Therapeutics, Audiocast, Q4'25

Egetis Therapeutics
Regulatory press release2/26/2026, 6:00 AM

Year-End Report January-December 2025

Egetis Therapeutics
Press release2/24/2026, 10:00 AM

Egetis Therapeutics to Present at Upcoming Investor Events

Egetis Therapeutics
Press release2/19/2026, 9:30 AM

Invitation to presentation of Egetis’ fourth quarter and year-end 2025 report on February 26, 2026

Egetis Therapeutics
Press release2/16/2026, 6:00 AM

Egetis provides update on progress with the development of Emcitate® (tiratricol) for MCT8 deficiency in Japan

Egetis Therapeutics
Press release2/4/2026, 2:25 PM

FDA's rare pediatric disease priority review program extended until 2029

Egetis Therapeutics
Regulatory press release1/29/2026, 6:00 AM

Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency

Egetis Therapeutics
Press release1/16/2026, 11:45 AM

Chairman of the Board of Egetis Therapeutics acquires shares

Egetis Therapeutics
Press release1/8/2026, 8:30 AM

Egetis Therapeutics to Host Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Egetis Therapeutics
Regulatory press release12/30/2025, 7:00 AM

Change in the number of ordinary shares and votes in Egetis Therapeutics

Egetis Therapeutics
Regulatory press release12/19/2025, 6:00 AM

Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency

Egetis Therapeutics
Press release12/17/2025, 12:35 PM

Egetis Therapeutics to move to the Nasdaq Stockholm Mid Cap segment

Egetis Therapeutics
Press release12/10/2025, 6:00 AM

Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate® Across Central, Eastern, and Southeastern Europe

Egetis Therapeutics
Press release12/4/2025, 9:55 AM

New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta

Egetis Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.